Treatment progress of peripheral T-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 71-73, 2021.
Article
em Zh
| WPRIM
| ID: wpr-882242
Biblioteca responsável:
WPRO
ABSTRACT
Peripheral T-cell lymphoma (PTCL) is a relatively common subtype of non-Hodgkin lymphoma in China. PTCL is clinically highly aggressive, and it progresses rapidly. The current treatment methods are ineffective and the overall prognosis is poor. The 62nd American Society of Hematology Annual Meeting reported on the progress of PTCL molecular targeted therapy and immunotherapy, including programmed death receptor 1/programmed death receptor ligand 1 antibodies, JAK inhibitors, brentuximab vedotin, etc. These novel drugs bring a better prospect for patients.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2021
Tipo de documento:
Article